公开(公告)号：US08506957B2

公开(公告)日：2013-08-13

申请号：US11792758

申请日：2005-12-07

申请人： Nicola Louise Leeds ,  Malcolm Andrew Ward ,  Sarah Joanna Tabrizi ,  Annette Dalrymple ,  Emma McGregor ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Byers

发明人： Nicola Louise Leeds ,  Malcolm Andrew Ward ,  Sarah Joanna Tabrizi ,  Annette Dalrymple ,  Emma McGregor ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Byers

IPC分类号： A61K39/395 ,  G01N33/68

CPC分类号： G01N33/6896 ,  G01N2800/2828 ,  G01N2800/56 ,  G01N2800/60

摘要： The invention relates to a method of diagnosis of Huntington's Disease in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an altered concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being selected from: Swiss Prot accession number: Protein name; P10909: Clusterin precursor; P00738: Haptoglobin precursor; P01009: Alpha-1-antitrypsin precursor; P01024: Complement C3 precursor; P01620: 1g kappa chain V-III region; P01834: 1 g kappa chain C region P01842: 1g lambda chain C regions; P01857: 1g gamma-1 chain C region; P01859: Ig gamma-2 chain C region; P01876: 1g alpha-1 chain C region P02647: Apolipoprotein A-I precursor; P02649: Apolipoprotein E precursor; P02652: Apolipoprotein A-II precursor; P02655: Apolipoprotein C-II precursor; P02656: Apolipoprotein C-II precursor P02671: Fibrinogen alpha/alpha-E chain precursor; P02763: Alpha-1-acid glycoprotein 1 precursor; P02766: Transthyretin precursor; P02768: Serum albumin precursor; P02787: Serotransferrin precursor; P04196: Histidine-rich glycoprotein precursor; P06727: Apolipoprotein A-IV precursor; P19652: Alpha-1-acid glycoprotein 2 precursor; P68871/P02042: Hemoglobin beta chain/Hemoglobin delta chain; P60709: Beta actin.

摘要翻译： 本发明涉及一种在人受试者的有效身体组织的诊断样本中诊断亨廷顿病的方法，其包括检测诊断样品中蛋白质的浓度变化，与对照人受试者的样品相比， 该蛋白质选自：瑞士抗原登录号：蛋白质名称; P10909：Clusterin前体; P00738：近红球蛋白前体; P01009：α-1-抗胰蛋白酶前体; P01024：补体C3前体; P01620：1gκ链V-III区; P01834：1g卡巴链C区P01842：1gλ链C区; P01857：1gγ-1链C区; P01859：Igγ-2链C区; P01876：1gα-1链C区P02647：载脂蛋白A-1前体; P02649：载脂蛋白E前体; P02652：载脂蛋白A-II前体; P02655：载脂蛋白C-II前体; P02656：载脂蛋白C-II前体P02671：纤维蛋白原α/α-E链前体; P02763：α-1-酸性糖蛋白1前体; P02766：曲氨酸蛋白前体; P02768：血清白蛋白前体; P02787：血清转铁蛋白前体; P04196：富含组氨酸糖蛋白前体; P06727：载脂蛋白A-IV前体; P19652：α-1酸性糖蛋白2前体; P68871 / P02042：血红蛋白β链/血红蛋白三角链; P60709：β肌动蛋白

公开(公告)号：US20080286263A1

公开(公告)日：2008-11-20

申请号：US11792758

申请日：2005-12-07

申请人： Nicola Louise Leeds ,  Malcolm Andrew Ward ,  Sarah Joanna Tabrizi ,  Annette Dalrymple ,  Emma McGregor ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Dyers

发明人： Nicola Louise Leeds ,  Malcolm Andrew Ward ,  Sarah Joanna Tabrizi ,  Annette Dalrymple ,  Emma McGregor ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Dyers

IPC分类号： A61K39/395 ,  C12Q1/02 ,  A61P25/00 ,  C07K1/26 ,  G01N33/53

CPC分类号： G01N33/6896 ,  G01N2800/2828 ,  G01N2800/56 ,  G01N2800/60

摘要： The invention relates to a method of diagnosis of Huntington's Disease in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an altered concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being selected from: Swiss Prot accession number: Protein name; P10909: Clusterin precursor; P00738: Haptoglobin precursor; P01009: Alpha-1-antitrypsin precursor; P01024: Complement C3 precursor; P01620: 1 g kappa chain V-III region; P01834: 1 g kappa chain C region P01842: 1 g lambda chain C regions; P01857: 1 g gamma-1 chain C region; P01859: Ig gamma-2 chain C region; P01876: 1 g alpha-1 chain C region P02647: Apolipoprotein A-I precursor; P02649: Apolipoprotein E precursor; P02652: Apolipoprotein A-II precursor; P02655: Apolipoprotein C-II precursor; P02656: Apolipoprotein C-II precursor P02671: Fibrinogen alpha/alpha-E chain precursor; P02763: Alpha-1-acid glycoprotein 1 precursor; P02766: Transthyretin precursor; P02768: Serum albumin precursor; P02787: Serotransferrin precursor; P04196: Histidine-rich glycoprotein precursor; P06727: Apolipoprotein A-IV precursor; P19652: Alpha-1-acid glycoprotein 2 precursor; P68871/P02042: Hemoglobin beta chain/Hemoglobin delta chain; P60709: Beta actin.

摘要翻译： 本发明涉及一种在人受试者的有效身体组织的诊断样本中诊断亨廷顿病的方法，其包括检测诊断样品中蛋白质的浓度变化，与对照人受试者的样品相比， 该蛋白质选自：瑞士抗原登录号：蛋白质名称; P10909：Clusterin前体; P00738：近红球蛋白前体; P01009：α-1-抗胰蛋白酶前体; P01024：补体C3前体; P01620：1g卡巴链V-III区; P01834：1g卡巴链C区P01842：1个λ链C区; P01857：1gγ-1链C区; P01859：Igγ-2链C区; P01876：1gα-1链C区P02647：载脂蛋白A-1前体; P02649：载脂蛋白E前体; P02652：载脂蛋白A-II前体; P02655：载脂蛋白C-II前体; P02656：载脂蛋白C-II前体P02671：纤维蛋白原α/α-E链前体; P02763：α-1-酸性糖蛋白1前体; P02766：曲氨酸蛋白前体; P02768：血清白蛋白前体; P02787：血清转铁蛋白前体; P04196：富含组氨酸糖蛋白前体; P06727：载脂蛋白A-IV前体; P19652：α-1酸性糖蛋白2前体; P68871 / P02042：血红蛋白β链/血红蛋白三角链; P60709：β肌动蛋白

公开(公告)号：US09028801B2

公开(公告)日：2015-05-12

申请号：US11792686

申请日：2005-12-07

申请人： Malcolm Andrew Ward ,  John Collinge ,  Graham Stuart Jackson ,  Emma McGregor ,  Nicola Louise Leeds ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Byers

发明人： Malcolm Andrew Ward ,  John Collinge ,  Graham Stuart Jackson ,  Emma McGregor ,  Nicola Louise Leeds ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Byers

IPC分类号： A61B5/145 ,  G01N33/48 ,  C07K14/805 ,  C07K14/75 ,  C07K14/705 ,  G01N33/68

CPC分类号： G01N33/6896 ,  G01N2800/2828 ,  G01N2800/56 ,  G01N2800/60

摘要： The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Acc. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Acc. No. P02023); or alpha-1-antitrypsin (SwissProt Acc. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Acc. No. P51884); alpha-fibrinogen precursor (SwissProt Acc. No. P02671); IGHG4 protein (Swiss Prot Acc. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed.

摘要翻译： 本发明涉及一种诊断样品中vCJD的方法，该方法是从人体受试者获取的有效身体组织的诊断样本中，其与检测样本中的蛋白质的浓度相比较，与对照人受试者相比， 蛋白质是：β-肌动蛋白（SwissProt Acc.P60709），载脂蛋白A-IV前体（SwissProt Acc.Po6727）; 由残基162-406组成的触珠蛋白β链（SwissProt Acc.P00738）; 血红蛋白β链（SwissProt Acc。编号P02023）; 或α-1-抗胰蛋白酶（SwissProt Acc。编号P01009）; 或与对照组，正常人受试者的样品，蛋白质是血浆蛋白酶（C1）抑制剂前体（SwissProt Acc.No.P05155））相比，诊断样品中蛋白质的浓度降低。 补充成分1的子成分（SwissProt Acc。No.P09871）; 丁酰胆碱酯酶前体（SwissProt Acc.Po6276）; 补体成分C4B（SwissProt Acc。No.P01028）; lumican（SwissProt Acc。No. P51884）; α-纤维蛋白原前体（SwissProt Acc。编号P02671）; IGHG4蛋白（Swiss Prot Acc。No.Q8TC63）或免疫球蛋白λ重链。 还公开了其它标记蛋白。

公开(公告)号：US20080213802A1

公开(公告)日：2008-09-04

申请号：US11792686

申请日：2005-12-07

申请人： Malcolm Andrew Ward ,  John Collinge ,  Graham Stuart Jackson ,  Emma McGregor ,  Nicola Louise Leeds ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Byers

发明人： Malcolm Andrew Ward ,  John Collinge ,  Graham Stuart Jackson ,  Emma McGregor ,  Nicola Louise Leeds ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Byers

IPC分类号： G01N33/53 ,  C12Q1/02 ,  C12Q1/46

CPC分类号： G01N33/6896 ,  G01N2800/2828 ,  G01N2800/56 ,  G01N2800/60

摘要： The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Ace. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Ace. No. P02023); or alpha-1-antitrypsin (SwissProt Ace. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Ace. No. P51884); alpha-fibrinogen precursor (SwissProt Ace. No. P02671); IGHG4 protein (Swiss Prot Ace. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed.

摘要翻译： 本发明涉及一种诊断样品中vCJD的方法，该方法是从人体受试者获取的有效身体组织的诊断样本中，其与检测样本中的蛋白质的浓度相比较，与对照人受试者相比， 蛋白质是：β-肌动蛋白（SwissProt Ace.No.P60709），载脂蛋白A-IV前体（SwissProt Acc.Po6727）; 由残基162-406组成的触珠蛋白β链（SwissProt Acc.P00738）; 血红蛋白β链（SwissProt Ace。编号P02023）; 或α-1-抗胰蛋白酶（SwissProt Ace.Po1009）; 或与对照组，正常人受试者的样品，蛋白质是血浆蛋白酶（C1）抑制剂前体（SwissProt Acc.No.P05155））相比，诊断样品中蛋白质的浓度降低。 补充成分1的子成分（SwissProt Acc。No.P09871）; 丁酰胆碱酯酶前体（SwissProt Acc.Po6276）; 补体成分C4B（SwissProt Acc。No.P01028）; lumican（SwissProt Ace。No. P51884）; α-纤维蛋白原前体（SwissProt Ace。编号P02671）; IGHG4蛋白（Swiss Prot Ace。No.Q8TC63）或免疫球蛋白λ重链。 还公开了其它标记蛋白。